ASLNuoro
Azienda socio-sanitaria locale

SALUTE/ ARES-AZIENDA REGIONALE DELLA S
PG/2022/25407 del 23/03/2022 ore 15:34
Mitt.: SC Servizio Farmaceutico Ospedali...
Dest.: S.C. SERVIZIO GIURIDICO AMMINISTR...
Class.: 1. Fasc.: 48 del 2022

, /03/2022 prot. n._____

AREA SOCIO SANITARIA LOCALE di NUORO
DIRETTORE GENERALE
Dott. Paolo Cannas

Farmacia Ospedaliera
P.O. "S. Francesco"
Nuoro
Tel. 0784240528

Farmacia Ospedaliera
P.O. "S. Camillo
Sorgono
Tel. 0784623328

Al Resp SC Giuridico Amministrativo d'Area
e p.c. al Resp. Dipartimento del Farmaco ARES
loro sedi

Oggetto: acquisto artesunato

Relativamente all'ordine 3-F1-2022-39, discendente dalla trattativa MEPA n.2022894 autorizzata dal Dip. Del Farmaco, si comunica che la ditta UNIPHARMA (vd allegati) non provvederà alla fornitura,pertanto si chiede di interpellare un secondo importatore (es ditta OTTOPHARMA o ditta FINTERNAZIONALE).
Ad ogni buon fine si allegato i preventivi forniti al momento della istruttoria di cui sarà necessario domandare conferma.

In attesa di riscontro si porgono
distinti saluti

I Dirigenti Farmacisti - SC Farmacia Ospedaliera – P.O. San Francesco

Drssa Pietrina Deiana assente

Drssa Paola Chessa

Drssa Sara Sanna

Dr Giuseppe Mulargia

Drssa Laura D.G. Milia

ASLNuoro
Azienda socio-sanitaria locale

NP 2022/106

Nuoro, 17/01/2022 prot. n. 106

Al Resp Dipartimento Farmaceutico
Dr.ssa N.A. Dicara
sede

AREA SOCIO SANITARIA
LOCALE di NUORO
DIRETTORE GENERALE
Dott. Paolo Cannas

Farmacia Ospedaliera
P.O. "S. Francesco"
Nuoro
Tel. 0784240528

Farmacia Ospedaliera
P.O. "S. Camillo
Sorgono
Tel. 0784623328

Oggetto: acquisto artesunato pz Rianimazione e scorta

Al fine di garantire la terapia di elezione per la paziente S.C., affetta da malaria grave, nonché per disporre di un ulteriore ciclo di terapia (vista la natura di farmaco estero e le potenziali condizioni di urgenza nell'utilizzo) si chiede autorizzazione all'acquisto di numero 60 fiale di artesunato 60mg fiale e.v.. Considerati il prezzo unitario, il minimo d'ordine, le spese di trasporto applicate e i tempi di consegna garantiti dai tre importatori preventivamente interpellati si propone quanto segue:

specialità ARTESUN 60MG IM/IV 5FL
fornitore UNIPHARMA SA
prezzo unitario €2,65 + IVA
spese di trasporto €30,00

PARERE FAVOREVOLE

In attesa di riscontro si porgono distinti saluti

I Dirigenti Farmacisti - SC Farmacia Ospedaliera – P.O. San Francesco

14/2/22

Drssa Pietrina Deiana assente

Drssa Paola Chessa

Drssa Sara Sanna

Dr Giuseppe Mulargia

Drssa Laura D.G. Milia

Oggetto: Affidamento fornitura del farmaco Artesun necessario all'U.O. Malattie Infettive del P.O.U San Francesco ASL Nuoro all'O.E. Unipharma SA
Mittente: "Dott.ssa Stefania Cabiddu" <stefania.cabiddu@aslnuoro.it>
Data: 14/03/2022, 12:42
A: <paola.chessa@atssardegna.it>

Si comunica che con delibera del Direttore Generale dell'ASL3 Nuoro ex art.47 L.R. 24/2000-ASL N. 3 Nuoro n. 45 del 14/03/2022, allegata alla presente, è stata affidata all'Operatore Economico Unipharma SA, la fornitura in oggetto, mediante Trattativa diretta MePa n. 2022894.

Lo scrivente Servizio ha provveduto in data 14/03/2022, a generare i contratto AREAS NUO/2022/29 con l'O.E. Unipharma SA , a valere sul quale vorrà il Servizio di Farmacia (richiesta acquisto prot. NP/2022/106 del 12.01.2022), secondo quanto di competenza, procedere ad emettere il formale ordine alla Ditta aggiudicataria e a curare la successiva procedura relativa alla liquidazione della fatture.

Cordiali Saluti.
Stefania Cabiddu

--
Dott.ssa Stefania Cabiddu
Collaboratore Amministrativo
ASSL N. 3 di Nuoro
Tel.: 0784 240974
e-mail:stefania.cabiddu@aslnuoro.it

Allegati:

PDEL_2022_0000050_DEL_N._45.pdf	388 kB
CONTRATTO 27.pdf	13,4 kB

℞

Artesunate Injection IP

RT-NET INJECTION 60mg/vial

Chemical Structure :



Molecular formula $C_{19}H_{28}O_8$=384.42

COMPOSITION :

Each vial contains:

Artesunate (Sterile) IP	60 mg

The pack contains :

1ml ampoule of	
Sodium Bicarbonate Injection IP	5% w/v
5ml ampoule of	
Sodium Chloride Injection IP	0.9% w/v

DESCRIPTION :

Artesunate is water soluble hemisuccinate derivative of artemisinin, an antimalarial principle extracted from leaves of the plant *Artemisia annua*. Artemisinin is a sesquiterpene lactone peroxide. It is a white crystalline powder, odourless and almost tasteless.

The chemical name is Dihydroartemisinin-10-ol hydrogen succinate.

PHARMACOLOGICAL ACTIONS :

ANTIMALARIAL ACTIVITY :

Artemisinin compounds are concentrated in parasitized erythrocytes. Endoperoxide bridge is essential for antimalarial activity. They are thought to cause free radical damage to the parasite membrane system, although the precise mechanism is unclear.

Artemisinin compounds act rapidly stopping parasite development and preventing subsequent cytoadherence.

Clinical effectiveness of artemisinin compounds have been confirmed in *P. vivax* and *P. falciparum* malaria (both in chloroquine sensitive and resistant strains). Artemisinin compounds are rapidly acting blood schizonticides for these species. They act early in the asexual parasite developmental cycle by destroying the early ring forms. They have no activity on persistent hepatic forms (hypnozoites) and on gametocytes. Their effectiveness in other species of malaria i.e. *P. ovale* and *P. malariae* is yet not fully evaluated.

CLINICAL PHARMACOKINETICS :

Plasma drug concentration decreases rapidly after intravenous administration of artesunate. The plasma half-life is about 30 minutes. It distributes widely throughout the body and with high concentration in intestines, liver and kidneys. Only small quantity is excreted in the urine and in the stools. It is mainly eliminated by metabolic

biotransformation.

INDICATIONS :

For use in severe malaria including cerebral malaria and as a second line treatment in chloroquine resistant malaria. Not to be used as a first line treatment of malaria.

DOSAGE AND ADMINISTRATION :

Falcinova injections are for intravenous or intramuscular use.

The usual dose of artesunate is 60mg daily. The first dose is doubled. The recommended dose in children is 1.2mg/kg. The usual duration of the treatment is 5 days. The duration of treatment is 7days in very serious and non-immune patients. If the patient is infected with high parasitaemia (RBC infection > 10%) an additional dose of 60mg should be given after 4-6 hours of first dose of 120mg.

The recrudescence rate is <10% in chloroquine resistant areas.

Before administration, artesunate powder is mixed with 1ml of 5% sodium bicarbonate and shaken for 2-3 minutes. After it dissolves completely and solution becomes clear, air is eliminated from the vial with a syringe and needle.

For IV use, add 5ml (and for IM use, add 2ml) of 5% dextrose or normal saline to make final concentration of 10mg/ml of artesunate (IM 20mg/ml).

For IV use, the required amount of drug is administered slowly at a rate of 3-4ml/minute.

It should be injected immediately after the powder of artesunate dissolves. If the solution appears cloudy or sediment occurs, it should not be used. It should not be used as an intravenous infusion.

PRECAUTIONS :

The results of animal experiments have shown some embryotoxic effect. Therefore, it should be used with extreme caution in pregnancy within the first three months.

ADVERSE REACTIONS :

No adverse reactions have been observed with the recommended dose till now. Transient reticulocytopenia may occur when dose in excess of 3.75mg/kg is given.

PRESENTATION :

Vial pack with 1ml ampoule of Sodium Bicarbonate Injection IP 5% w/v & 5ml ampoule of Sodium Chloride Injection IP 0.9% w/v

KEEP IN A COOL PLACE

PROTECT FROM LIGHT

Zyphar's
Pharmaceutics

Zyphar's Pharmaceutics Pvt. Ltd.
Gat # 1194, H # 1093, 1st Floor, Wadki,
Tal: Haveli, Dist- Pune, (M.S), India
E-mail : info@zyphars.com

Mfg. under technical guidance
of KALIBERR LABS Pvt. Ltd. by :
Om Biomedic Pvt. Ltd.
Plot No. 68, 69,82 & 83, Sec-6A,
I.I.E,SIDCUL, Haridwar - 249403 (U.K.)

ASLNuoro
Azienda socio-sanitaria locale

SALUTE/ ARES-AZIENDA REGIONALE DELLA S
PG/2022/26407 del 23/03/2022 ore 15:34
Mitt.: SC Servizio Farmaceutico Ospedali...
Dest.: S.C. SERVIZIO GIURIDICO AMMINISTR...
Class.: 1. Fasc.: 48 del 2022

, /03/2022 prot. n.

AREA SOCIO SANITARIA LOCALE di NUORO
DIRETTORE GENERALE
Dott. Paolo Cannas

Farmacia Ospedaliera
P.O. "S. Francesco"
Nuoro
Tel. 0784240528

Farmacia Ospedaliera
P.O. "S. Camillo
Sorgono
Tel. 0784623328

Al Resp SC Giuridico Amministrativo d'Area
e p.c. al Resp. Dipartimento del Farmaco ARES
loro sedi

Oggetto: acquisto artesunato

Relativamente all'ordine 3-F1-2022-39, discendente dalla trattativa MEPA n.2022894 autorizzata dal Dip. Del Farmaco, si comunica che la ditta UNIPHARMA (vd allegati) non provvederà alla fornitura,pertanto si chiede di interpellare un secondo importatore (es ditta OTTOPHARMA o ditta FINTERNAZIONALE).
Ad ogni buon fine si allegato i preventivi forniti al momento della istruttoria di cui sarà necessario domandare conferma.

In attesa di riscontro si porgono
distinti saluti

I Dirigenti Farmacisti - SC Farmacia Ospedaliera – P.O. San Francesco

Drssa Pietrina Deiana assente

Drssa Paola Chessa

Drssa Sara Sanna

Dr Giuseppe Mulargia

Drssa Laura D.G. Milia

IL DIRETTORE DIPARTIMENTO DEL FARMACO
Dott.ssa Ninfa Antonia Di Cara

SALUTE/ ARES-AZIENDA REGIONALE DELLA S
NP/2022/917 del 23/03/2022 ore 15,38
Mitt.: SC Servizio Farmaceutico Ospedali...
Ass.: Dipartimento del Farmaco
Class.: 1. Fasc.: 48 del 2022

It should be injected immediately after the powder of artesunate dissolves. If the solution appears cloudy or sediment occurs, it should not be used. It should not be used as an intravenous infusion.

PRECAUTIONS :

The results of animal experiments have shown some embryotoxic effect. Therefore, it should be used with extreme caution in pregnancy within the first three months.

ADVERSE REACTIONS :

No adverse reactions have been observed with the recommended dose till now. Transient reticulocytopenia may occur when dose in excess of 3.75mg/kg is given.

PRESENTATION :

Vial pack with 1 ml ampoule of Sodium Bicarbonate Injection IP 5% w/v & 5 ml ampoule of Sodium Chloride Injection IP 0.9 % w/v

Store below 30°C. Protect from light.

Zydus Cadila

Marketed by:
Cadila Healthcare Limited,
"Zydus Tower", Satellite Cross Roads,
Ahmedabad - 380 015.

Manufactured in India by:
Alconi India Pvt. Ltd.
Vill. & P. O. Nihalgarh,
Tehsil Pachia Sahib, Distt. Sirmour,
Himachal Pradesh-173025, India.

FOR HOSPITAL USE ONLY

Artesunate Injection

Falciga Injection

Chemical Structure :



Molecular formula $C_{19}H_{28}O_8$ - 384.4

COMPOSITION :

Each vial contains :

Artesunate (Sterile) IP	60 mg

The pack contains :

1 ml ampoule of Sodium Bicarbonate Injection IP	5% w/v
5 ml ampoule of Sodium Chloride Injection IP	0.9 % w/v

DESCRIPTION :

Artesunate is water soluble hemisuccinate derivative of artemisinin, (QINGHAOSU), an antimalarial principle extracted from leaves of the plant Artemisia annua. Artemisinin is a sesquiterpene lactone peroxide. It is a white crystalline powder, odourless and almost tasteless.

The chemical name is Dihydroartemisinin-10-ol hydrogen succinate.

PHARMACOLOGICAL ACTIONS :

ANTIMALARIAL ACTIVITY :

Artemisinin compounds are concentrated in parasitized erythrocytes. Endoperoxide bridge is essential for antimalarial activity. They are thought to cause free radial damage to the parasite membrane system, although the precise mechanism is unclear. Artemisinin compounds act rapidly stopping parasite development and preventing subsequent cytoadherance.

Clinical effectiveness of artemisinin compounds have been confirmed in P. vivax and P. falciparum malaria (both in chloroquine sensitive and resistant strains). Artemisinin compounds are rapidly acting blood schizonticides for these species. They act selly in the asexual parasite developmental cycle by destroying the early ring forms. They have no activity on persistent hepatic forms (hypnozoites) and on gametocytes. Their effectiveness in other species of malaria i.e. P. ovale and P. malariae is yet not fully evaluated.

CLINICAL PHARMACOKINETICS :

Plasma drug concentration decreases rapidly after intravenous administration of artesunate. The plasma half-life is about 30 minutes. It distributes widely throughout the body and with high concentration in intestines, liver and kidneys. Only small quantity is excreted in the urine and in the stools. It is mainly eliminated by metabolic biotransformation.

INDICATIONS :

For use in severe malaria including cerebral malaria and as a second line treatment in chloroquine resistant malaria. Not to be used as a first line treatment of malaria.

DOSAGE AND ADMINISTRATION :

Kelolgo injections are for intravenous or intramuscular use.

The usually recommended dose of the drug is 2.4 mg/kg (i.e. 120mg in adults) given initially and then repeated after 12 and 24 hours and once daily thereafter until patient is able to tolerate oral medications when an ACT (Artemisinin based Combination Therapy) is given to ensure a curative treatment.

The recrudescence rate is < 10% in chloroquine resistant areas.

Before administration, artesunate powder is mixed with 1ml of 5% sodium bicarbonate and shaken for 2-3 minutes. After it dissolves completely and solution becomes clear, air is eliminated from the vial with a syringe and needle.

For I.v. use, add 5ml (and for I.m. use add 2ml) of 5% dextrose or normal saline to make final concentration of 10mg/ml of artesunate (I.m. 20mg/ml).

For I.v. use, the required amount of drug is administered slowly at a rate of 3-4ml/minute.